Current topics in autoimmune hepatitis

Digestive and Liver Disease

Volumn 42, Issue 11, 2010, Pages 757-764

  Muratori, Luigi ^a   Muratori, Paolo ^a   Granito, Alessandro ^a   Pappas, Giorgios ^a   Cassani, Fabio ^a   Lenzi, Marco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Autoantibodies; Autoimmune hepatitis; Diagnosis; Liver; Therapy

Indexed keywords

ACTIN ANTIBODY; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BUDESONIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFLAZACORT; IMMUNOGLOBULIN; LIVER ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; TIOGUANINE; URSODEOXYCHOLIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; LIVER CYTOSOL; MEDICAL RESEARCH; MOLECULAR RECOGNITION; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SHORT SURVEY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; BUDESONIDE; CHOLANGITIS, SCLEROSING; CYCLOSPORINE; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MICE; MYCOPHENOLIC ACID; RATS; TRANSAMINASES;

EID: 77957280868     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.05.019     Document Type: Short Survey

References (130)

1. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
2. Johnson P.J., McFarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18:998-1005.
3. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
4. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
5. Czaja A.J. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008, 48:1540-1548.
6. Muratori P., Granito A., Pappas G., et al. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology 2009, 49:1782-1783.
7. Wiegard C., Schramm C., Lohse A.W. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis 2009, 29:254-261.
8. Miyake Y., Iwasaki Y., Kobashi H., et al. Clinical features of autoimmune hepatitis diagnosed based on simplified criteria of the International Autoimmune Hepatitis Group. Dig Liver Dis 2010, 42:210-215.
9. Czaja A.J., Freese D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002, 36:479-497.
10. Yeoman A.D., Longhi M.S., Heneghan M.A. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther 2010, 31:771-787.
11. Verma S., Gunuwan B., Mendler M., et al. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004, 99:1510-1516.
12. Montano-Loza A.J., Carpenter H.A., Czaja A.J. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007, 102:1005-1012.
13. Miyake Y., Iwasaki Y., Terada R., et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005, 43:951-957.
14. Muratori P., Granito A., Quarneti C., et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009, 50:1210-1218.
15. Verma S. In type 1 autoimmune hepatitis (AIH), should remission be redefined as normalization of transaminases?. J Hepatol 2006, 44:819-820. 820-1.
16. Al-Chalabi T., Heneghan M.A. Remission in autoimmune hepatitis: what is it, and can it ever be achieved?. Am J Gastroenterol 2007, 102:1013-1015.
17. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology, in press.
18. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008, 48:835-847.
19. Zhang Y.G., Wang B.E., Wang T.L., et al. Assessment of hepatic fibrosis by transient elastography in patients with chronic hepatitis B. Pathol Int 2010, 60:284-290.
20. Anastasiou J., Alisa A., Virtue S., et al. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Eur J Gastroenterol Hepatol 2010, 22:474-480.
21. Obara N., Ueno Y., Fukushima K., et al. Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol 2008, 43:720-728.
22. Romanque P., Stickel F., Dufour J.F. Disproportionally high results of transient elastography in patients with autoimmune hepatitis. Liver Int 2008, 28:1177-1178.
23. Bianchi F.B., Muratori P., Muratori L. New autoantibodies and autoantigens in autoimmune hepatitis. Clin Liver Dis 2002, 6:785-797.
24. Vergani D., Alvarez F., Bianchi F.B., et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004, 41:677-683.
25. Bogdanos D.P., Mieli-Vergani G., Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009, 29:241-253.
26. Martini E., Abuaf N., Cavalli F., et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988, 8:1662-1666.
27. Manns M., Gerken G., Kyriatsoulis A., et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987, 1:292-294.
28. Muratori L., Cataleta M., Muratori P., et al. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. J Immunol Methods 1995, 187:259-264.
29. Muratori L., Cataleta M., Muratori P., et al. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998, 42:721-726.
30. Bridoux-Henno L., Maggiore G., Johanet C., et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004, 2:825-830.
31. Lapierre P., Hajoui O., Homberg J.C., et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999, 116:643-649.
32. Muratori L., Sztul E., Muratori P., et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001, 34:494-501.
33. Lapierre P., Johanet C., Alvarez F. Characterization of the B cell response of patients with anti-liver cytosol autoantibodies in type 2 autoimmune hepatitis. Eur J Immunol 2003, 33:1869-1878.
34. Lapierre P., Djilali-Saiah I., Vitozzi S., et al. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology 2004, 39:1066-1074.
35. Beland K., Lapierre P., Marceau G., et al. Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection. J Autoimmun 2004, 22:159-166.
36. Wies I., Brunner S., Henninger J., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000, 355:1510-1515.
37. Costa M., Rodriguez-Sanchez J.L., Czaja A.J., et al. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol 2000, 121:364-374.
38. Volkmann M., Martin L., Baurle A., et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 2001, 33:591-596.
39. Gelpi C., Sontheimer E.J., Rodriguez-Sanchez J.L. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A 1992, 89:9739-9743.
40. Herkel J., Heidrich B., Nieraad N., et al. Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. Hepatology 2002, 35:403-408.
41. Ballot E., Homberg J.C., Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000, 33:208-215.
42. Ma Y., Okamoto M., Thomas M.G., et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002, 35:658-664.
43. Vitozzi S., Lapierre P., Djilali-Saiah I., et al. Anti-soluble liver antigen (SLA) antibodies in chronic HCV infection. Autoimmunity 2004, 37:217-222.
44. Bottazzo G.F., Florin-Christensen A., Fairfax A., et al. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 1976, 29:403-410.
45. Granito A., Muratori L., Muratori P., et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006, 59:280-284.
46. Muratori P., Muratori L., Agostinelli D., et al. Smooth muscle antibodies and type 1 autoimmune hepatitis. Autoimmunity 2002, 35:497-500.
47. Kerkar N., Hadzic N., Davies E.T., et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998, 351:409-413.
48. Andries S., Casamayou L., Sempoux C., et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001, 72:267-272.
49. Gupta P., Hart J., Millis J.M., et al. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001, 71:664-668.
50. Heneghan M.A., Portmann B.C., Norris S.M., et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001, 34:464-470.
51. Hernandez H.M., Kovarik P., Whitington P.F., et al. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001, 32:131-136.
52. Miyagawa-Hayashino A., Haga H., Egawa H., et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004, 78:128-135.
53. Aguilera I., Wichmann I., Sousa J.M., et al. Antibodies against glutathione S-transferase T1 in patients with immune hepatitis after liver transplantation. Transplant Proc 2003, 35:712.
54. Aguilera I., Sousa J.M., Gavilan F., et al. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl 2004, 10:1166-1172.
55. Aguilera I., Sousa J.M., Gavilan F., et al. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant Proc 2005, 37:3968-3969.
56. Salcedo M., Rodriguez-Mahou M., Rodriguez-Sainz C., et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transpl 2009, 15:530-539.
57. Granito A., Vannini A., Quarneti C., et al. Clinical impact and behaviour of serum autoantibodies in adult liver transplantation. J Hepatol 2010, 52(Suppl. 1):S197-S198.
58. McNair A.N., Moloney M., Portmann B.C., et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998, 93:777-784.
59. Gohlke F., Lohse A.W., Dienes H.P., et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996, 24:699-705.
60. Muratori L., Cassani F., Pappas G., et al. The hepatitic/cholestatic " overlap" syndrome: an Italian experience. Autoimmunity 2002, 35:565-568.
61. Olsson R., Glaumann H., Almer S., et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009, 20:190-196.
62. Lohse A.W., zum Buschenfelde K.H., Franz B., et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999, 29:1078-1084.
63. Chazouilleres O., Wendum D., Serfaty L., et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
64. Talwalkar J.A., Keach J.C., Angulo P., et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002, 97:1191-1197.
65. Twaddell W.S., Lefkowitch J., Berk P.D. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome. Semin Liver Dis 2008, 28:128-134.
66. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.
67. Muratori P., Granito A., Pappas G., et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009, 104:1420-1425.
68. Efe C., Purnak T., Ozaslan E., et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2010, 105:226.
69. Nezu S., Tanaka A., Yasui H., et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2006, 21:1448-1454.
70. Montano-Loza A.J., Carpenter H.A., Czaja A.J. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol 2008, 42:1047-1053.
71. Mishima S., Omagari K., Ohba K., et al. Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study. Hepatogastroenterology 2008, 55:221-227.
72. O'Brien C., Joshi S., Feld J.J., et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008, 48:550-556.
73. Czaja A.J., Muratori P., Muratori L., et al. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004, 24:322-329.
74. Bittencourt P.L., Farias A.Q., Porta G., et al. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol 2008, 42:300-305.
75. Abdalian R., Dhar P., Jhaveri K., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008, 47:949-957.
76. Gregorio G.V., Portmann B., Karani J., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33:544-553.
77. Montano-Loza A.J., Carpenter H.A., Czaja A.J. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007, 46:1138-1145.
78. Angulo P., Maor-Kendler Y., Lindor K.D. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002, 35:1494-1500.
79. Bjornsson E., Olsson R., Bergquist A., et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008, 134:975-980.
80. Czaja A.J. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2009, 3:269-291.
81. Kanzler S., Gerken G., Dienes H.P., et al. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis-report of three cases. Z Gastroenterol 1997, 35:571-578.
82. Burak K.W., Urbanski S.J., Swain M.G. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998, 29:990-993.
83. Kerkar N., Dugan C., Rumbo C., et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005, 5:1085-1089.
84. Santos E.S., Arosemena L.R., Raez L.E., et al. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006, 26:625-629.
85. Carmassi F., Morale M., Puccetti R., et al. Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. Clin Exp Rheumatol 1992, 10:13-17.
86. Rebollo Bernardez J., Cifuentes Mimoso C., Pinar Moreno A., et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999, 91:630-638.
87. Nakamura K., Yoneda M., Yokohama S., et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998, 13:490-495.
88. Miyake Y., Iwasaki Y., Kobashi H., et al. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int 2009, 3:556-562.
89. de Boer N.K., de Graaf P., Wilhelm A.J., et al. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment. Aliment Pharmacol Ther 2005, 22:447-451.
90. de Boer N.K., van Nieuwkerk C.M., Aparicio Pages M.N., et al. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol Hepatol 2005, 17:457-461.
91. Fernandes N.F., Redeker A.G., Vierling J.M., et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999, 94:241-248.
92. Alvarez F., Ciocca M., Canero-Velasco C., et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999, 30:222-227.
93. Cuarterolo M., Ciocca M., Velasco C.C., et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006, 43:635-639.
94. Sciveres M., Caprai S., Palla G., et al. Effectiveness and safety of cyclosporine as therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther 2004, 19:209-217.
95. Ritter M.L., Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 2009, 11:290-297.
96. Richardson P.D., James P.D., Ryder S.D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000, 33:371-375.
97. Devlin S.M., Swain M.G., Urbanski S.J., et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004, 18:321-326.
98. Inductivo-Yu I., Adams A., Gish R.G., et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007, 5:799-802.
99. Chatur N., Ramji A., Bain V.G., et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005, 25:723-727.
100. Hennes E.M., Oo Y.H., Schramm C., et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. Am J Gastroenterol 2008, 103:3063-3070.
101. Hlivko J.T., Shiffman M.L., Stravitz R.T., et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008, 6:1036-1040.
102. Wolf D.C., Bojito L., Facciuto M., et al. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009, 54:2519-2522.
103. Aw M.M., Dhawan A., Samyn M., et al. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009, 51:156-160.
104. Spencer C.M., McTavish D., Budesonide A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995, 50:854-872.
105. McKeage K., Goa K.L. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults. Drugs 2002, 62:2263-2282.
106. Seow C.H., Benchimol E.I., Griffiths A.M., et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008, [CD000296].
107. Danielsson A., Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994, 8:585-590.
108. Czaja A.J., Lindor K.D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000, 119:1312-1316.
109. Wiegand J., Schuler A., Kanzler S., et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005, 25:927-934.
110. Geier A., Gartung C., Dietrich C.G., et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003, 9:2681-2685.
111. Csepregi A., Rocken C., Treiber G., et al. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006, 12:1362-1366.
112. Zandieh I., Krygier D., Wong V., et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008, 22:388-392.
113. Manns M.P., Bahr M.J., Woynarowski M., et al. Budesonide 3mg tid is superior to prednisone in combination with azathioprine in the treatment of autoimmune hepatitis. J Hepatol 2008, 48:S369.
114. Manns M.P., Woynarowski M., Kreisel W., et al. Budesonide 3mg bid in combination with azathioprine as maintenance treatment of autoimmune hepatitis-final results of a large multicenter international trial. Hepatology 2008, 48:376A-377A.
115. Shevach E.M. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000, 18:423-449.
116. Piccirillo C.A., Shevach E.M. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004, 16:81-88.
117. Piccirillo C.A. Regulatory T cells in health and disease. Cytokine 2008, 43:395-401.
118. Piccirillo C.A., d'Hennezel E., Sgouroudis E., et al. CD4+Foxp3+ regulatory T cells in the control of autoimmunity: in vivo veritas. Curr Opin Immunol 2008, 20:655-662.
119. Longhi M.S., Hussain M.J., Mitry R.R., et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006, 176:4484-4491.
120. Longhi M.S., Ma Y., Bogdanos D.P., et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004, 41:31-37.
121. Longhi M.S., Ma Y., Mitry R.R., et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005, 25:63-71.
122. Longhi M.S., Meda F., Wang P., et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008, 47:581-591.
123. Ferri S, Longhi MS, De Molo C, et al. A multifaceted imbalance of T-cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology, in press.
124. Christen U., Hintermann E., Jaeckel E. New animal models for autoimmune hepatitis. Semin Liver Dis 2009, 29:262-272.
125. Hardtke-Wolenski M., Jaeckel E. Mouse models for experimental autoimmune hepatitis: limits and chances. Dig Dis 2010, 28:70-79.
126. Lapierre P., Beland K., Djilali-Saiah I., et al. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun 2006, 26:82-89.
127. Lapierre P., Beland K., Martin C., et al. Forkhead box p3(+) regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis. Hepatology 2010, 51:1789-1798.
128. Christen U., Holdener M., Hintermann E. Cytochrome P450 2D6 as a model antigen. Dig Dis 2010, 28:80-85.
129. Holdener M., Hintermann E., Bayer M., et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008, 205:1409-1422.
130. Czaja A.J. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci 2010, [Epub ahead of print].